Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 28 July 2017 | By Michael Mezher
The European Medicines Agency (EMA) on Friday released a concept paper for public consultation outlining issues it plans to address in an upcoming guideline on the challenges in developing companion diagnostics for personalized medicines.
Specifically, EMA says its guideline will address the development of companion diagnostics for precision medicines in the clinical development and post-approval phases, and will include a glossary defining terms used in the guideline as well as in the IVDR.
Once adopted, EMA says the guideline will replace its existing reflection paper on the co-development of pharmacogenomics markers and assays released in 2010.
According to the agency, the decision to use a personalized medicine hinges on the use of companion diagnostics to determine whether a patient will benefit from a medicine, or alternatively whether the patient is at a higher risk for adverse reactions to the treatment.
"It is very important to clarify how evidence to support the validation of a companion diagnostic can be generated during the development of a medicine," EMA says.
However, EMA is not directly involved in authorizing companion diagnostics, as they are treated as in vitro diagnostic medical devices in the EU and can be marketed after being CE marked.
But, the agency says the new EU in vitro diagnostic regulation (IVDR) "foresees cooperation between medicines regulators and EU notified bodies … in the evaluation of new companion diagnostics to obtain the CE label."
According to EMA, drug and diagnostic developers oftentimes begin work on their products independently, and come together "only superficially towards the end" of the development phase, which the agency says is not ideal.
EMA also says it hopes developing guidance in this area will lead to more "close knit development programmes."
EMA, Concept Paper
Tags: Companion Diagnostics, CDx, Precision Medicine, Biomarkers
Regulatory Focus newsletters
All the biggest regulatory news and happenings.